Cullinan Therapeutics (CGEM) vs Electra Therapeutics (ETRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cullinan Therapeutics is the larger company by market cap ($577.1 million vs $509.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | ETRA |
|---|---|---|
| Share price | $8.89 | $8.11 |
| Market cap | $577.15M | $509.85M |
| 1-day change | -1.98% | -9.28% |
| YTD return | -14.11% | — |
| 1-year return | -6.12% | — |
| 5-year return | -51.21% | — |
| EPS (TTM) | $-3.09 | $-35.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-219.88M | — |
| 52-week high | $23.19 | $15.50 |
| 52-week low | $8.47 | $6.87 |
| Distance from 52-week high | -61.66% | -47.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +285.49% | +309.37% |
| Average volume | 997.14K | 559.28K |
| Shares outstanding | 64.92M | 62.87M |
| Employees | 109 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CGEM vs ETRA FAQ
Which is bigger, Cullinan Therapeutics or Electra Therapeutics?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $577.15M compared with $509.85M for Electra Therapeutics (ETRA).
Are Cullinan Therapeutics and Electra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.